ARTFEED — Contemporary Art Intelligence

AI Companies Race to Develop Autonomous Scientific Researchers

ai-technology · 2026-04-22

Autonomous scientific researchers are being developed by AI firms and academic institutions. Google DeepMind's AlphaFold, under the leadership of CEO Demis Hassabis and director John Jumper, was awarded the 2024 Nobel Prize in Chemistry for its ability to predict protein structures. In October 2025, OpenAI established an AI-for-science team focused on autonomous research, while Anthropic unveiled new Claude features for biological sciences. In February 2025, OpenAI introduced GPT‑Rosalind, and Google launched its AI co-scientist tool. Stanford's AI for Science Lab, directed by James Zou, developed a 'virtual lab' for creating antibody fragments targeting SARS-CoV-2. In February 2026, OpenAI integrated GPT-5 with Ginkgo Bioworks' automated labs, resulting in a 40% decrease in protein synthesis costs. A study in Nature cautions that AI might limit the scope of scientific investigation.

Key facts

  • AI companies justify their work by citing potential for AI-enabled scientific breakthroughs like curing cancer.
  • Large language models (LLMs) currently assist scientists by finding studies, drafting articles, and writing code.
  • The ambition is to create AI systems that act as full team members or initiate research with minimal human guidance.
  • Google DeepMind's AlphaFold won the 2024 Nobel Prize in Chemistry for predicting protein 3D structures.
  • OpenAI launched an AI-for-science team in October 2025, calling an autonomous researcher its 'North Star'.
  • Anthropic announced Claude features for biological sciences in October 2025.
  • OpenAI released GPT‑Rosalind, a specialized scientific model, and Google released an AI co-scientist tool in February 2025.
  • AI-for-science systems often use multiple specialized agents, like Google's supervisor, generation, and ranking agents.
  • Stanford's AI for Science Lab created a 'virtual lab' of agents that designed antibody fragments for SARS-CoV-2.
  • AI agents cannot physically run lab experiments, a limitation addressed by linking LLMs to robotic labs.
  • OpenAI connected GPT-5 to Ginkgo Bioworks' automated labs in February 2026 for iterative experiment proposal and interpretation.
  • The GPT-5/Ginkgo system ran many experiments and found a recipe reducing a protein's synthesis cost by 40%.
  • A Nature study found AI adoption might reduce the diversity of scientific topics investigated.
  • AI excels at analyzing existing data, potentially steering scientists toward established research areas.
  • Problems less amenable to AI analysis might receive less attention from scientists.
  • Integrating AI effectively into science is more than a technical problem; it requires effort to maintain scientific diversity.

Entities

Artists

  • Demis Hassabis
  • John Jumper
  • James Zou

Institutions

  • Google DeepMind
  • OpenAI
  • Anthropic
  • Stanford's AI for Science Lab
  • Ginkgo Bioworks
  • Nature

Sources